Literature DB >> 11293117

The antiviral activity of antibodies in vitro and in vivo.

P W Parren1, D R Burton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11293117      PMCID： PMC7131048          DOI： 10.1016/s0065-2776(01)77018-6

Source DB:  PubMed          Journal:  Adv Immunol        ISSN： 0065-2776            Impact factor:   3.543


× No keyword cloud information.
  249 in total

1.  THE INTERACTION BETWEEN VIRUS AND ANTIBODY. II. MECHANISM OF THE REACTION.

Authors:  K J LAFFERTY
Journal:  Virology       Date:  1963-09       Impact factor: 3.616

2.  Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.

Authors:  K E Wright; M J Buchmeier
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

3.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

Review 4.  HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.

Authors:  J P Moore; D D Ho
Journal:  AIDS       Date:  1995       Impact factor: 4.177

Review 5.  Role of complement in HIV infection.

Authors:  H Stoiber; A Clivio; M P Dierich
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.

Authors:  L Lefrancois
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

9.  Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; V G Hemming; R L Horswood; P A Baron; R M Chanock
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody.

Authors:  T J Smith; N H Olson; R H Cheng; H Liu; E S Chase; W M Lee; D M Leippe; A G Mosser; R R Rueckert; T S Baker
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103
View more
  109 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

5.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

6.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

7.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

Review 9.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.